Seres therapeutics announces fda clearance of ind for ser-155, an investigational microbiome therapeutic for the prevention of antibiotic-resistant bacterial infections and graft-versus-host disease (gvhd)

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, announces the u.s. food and drug administration (fda) has indicated studies for ser-155 may proceed under an investigational new drug (ind) application. ser-155 is an investigational oral, rationally-designed, cultivated microbiome therapeutic designed to reduce the incidence of gastrointestinal antibiotic-resistant bacterial infections, bacteremia and graft-versus-host disease
MCRB Ratings Summary
MCRB Quant Ranking